Deutsche Beteiligungs AG

(SDAX, Financial Services)



Hold		Value Indicators:	EUR	Share data:		Description:	
Hold	(Buy)	SotP 18e:	33.50	Bloomberg:	DBAN GR	Private equity both as an advisor an	
00.50		NAV 18e:	28.33	Reuters:	DBANn.DE	as a co-investor focused of	on the
EUR 33.50	(EUR 35.00)			ISIN: D	E000A1TNUT7	German Mittelstand	
		Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2016/17e
		Market cap:	427	Freefloat	75.0 %	Beta:	1.0
Price	EUR 31.10	No. of shares (m):	14	Rossmann Beteiligungs G	SmbH 19.9 %	Price / Book:	1.2 x
Upside	7.7 %	EV:	385	Ricardo Portabella	5.0 %	Equity Ratio:	92 %
- point		Freefloat MC:	320	JP Morgan Asset Managemen	nt 3.0 %		
		Ø Trad. Vol. (30d):	429.31 th	Red Rocks	2.9 %		

Feedback analyst meeting: Fully valued; Down to HOLD; PT EUR 33.50 (35.00)

Final figures FY /2015/16:				ı		
EUR m (year end 30.09.)	FY 15/16	FY 14/15	yoy	Q4 15/16	Q4 14/15	yoy
Net results of investment activity	60.1	29.2	106%	27.1	-0.2	n.m
Fee income of fund management and advisory services	18.3	19.2	-4.5%	4.4	3.2	36.19
Net result of fund services and investment activity	78.5	48.4	62.1%	31.6	3.0	9.
EBT	50.0	27.1	84.8%	23.8	-1.3	n.n
Net income	50.2	27.0	85.6%	23.8	-1.3	n.n
EPS	3.65	1.98	84.3%	1.74	-0.09	n.n
NAV per share	28.18	22.56	24.9%	28.18	22.56	259

Comment on Figures:

- Net result of investment activities: EUR 27.3m positive swing in Q4: following a disappointing Q3, a recovery in valuation multiples significantly helped, adding EUR 16m, following a EUR 10.4m loss in Q3. A further EUR 7m were booked in Q4 from earnings improvements in the portfolio companies.
- Fee income was impacted by a lower base due to disposals from fund DBAG V
- FY net income of EUR 50.2m, is in the middle of the preliminary range released mid-October of EUR 48-52m

Private Equity Investments: Five investments were announced in FY 15/16 (three MBOs, two growth financings), two of which closed after 30.09, for total investment commitments from DBAG's balance sheet of EUR 53.0m of which EUR 32.6m was disbursed as of 30.09. The portfolio value, comprising 25 companies, was up by 18% to EUR 302.6m/EUR 22 per share, (main building blocks: +EUR 33m in investments, - EUR 54.4m in divestments, +EUR 46.6m in earnings improvements, and +EUR 16m form changes in valuation multiples). DBAG has some EUR 278m in coinvestment commitments outstanding, including EUR 200m for the EUR 1 billion DBAG VII launched in July. Liquidity, including announced but not closed transactions (Broetje Automation and Grohmann), currently amounts to EUR 170m and covers investment requirements for the next three years.


Fund investment services: FY 15/16 saw the launch of DBAG VII comprising a EUR 808m main fund and a EUR 200m top-up fund, enabling DBAG to move quicker on larger transactions rather than having to arrange co-investor commitment in the heat of the transaction. The fundraising closed within three months. 80% of investors were previously invested in DBAG funds, which highlights DBAG's standing in the private equity community.

Outlook: Moderately lower 16/17 net income on a comparable basis (EUR 44.4m for FY 15/16), i.e. excluding gains on disposals and further multiples expansion. On a mid-term horizon, net income and return on NAV will be "significantly" higher than in 2016/17. Our assumptions are lower given portfolio valuation uncertainties. The sum-of-the parts methodology, based on our new estimates, yields a fair value per share based on 2018e estimates of EUR 33.50 (35.00). The share is fairly valued at current levels and is now rated Hold (Buy) with an attractive 3.8% dividend yield.

Changes in Estimates:				
FY End: 30.9. in EUR m	2016/17e (old)	+/-	2017/18e (old)	+/-
Net result of fund services and investment activity	71	0.4 %	82	-4.8 %
EBIT	48	-9.7 %	59	-16.8 %
Net in come	48	-11.4 %	59	-18.2 %
EPS	3.21	-11.5 %	3.92	-18.1 %
NAV per share	26.72	-1.5 %	29.61	-4.3 %

Comment on Changes:

- EPS 2016/2017 revised down 11.5% to reflect a cost base more in line with actual 15/16 numbers.
- EPS 2017/18 revised down 18% given more conservative valuation gains assumptions and a higher cost base than originally anticipated.




Rel. Performance vs SDAX:	
1 month:	-3.2 %
6 months:	14.1 %
Year to date:	2.1 %
Trailing 12 months:	4.1 %
Company events:	

Company events:	
09.02.17	Q1
22.02.17	AGM
09.05.17	Q2
01.08.17	Q3

FY End: 30.9. in EUR m	CAGR (15/16-18/19e)	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/19e
Net result of fund services and	3.3 %	60	76	48	78	72	78	87
investment activity	'			00	00	40	40	- 4
Net result investment activity		41	55	29	60	43	46	54
Fee income fund services		19	22	19	18	29	33	32
EBIT	3.5 %	34	48	27	51	44	49	56
EBT		34	48	27	50	43	49	55
Net income	3.2 %	32	48	27	50	43	48	55
EPS	0.1 %	2.36	3.51	1.98	3.65	2.84	3.21	3.66
DPS	0.0 %	1.20	2.00	1.00	1.20	1.20	1.20	1.20
Dividend Yield		6.2 %	9.5 %	3.6 %	4.3 %	3.9 %	3.9 %	3.9 %
NAV per share		20.32	22.16	22.16	26.91	26.32	28.33	30.79
Return on NAV		11.2 %	15.9 %	9.9 %	27.2 %	2.4 %	12.8 %	13.5 %
P/E		8.2 x	6.0 x	14.0 x	7.6 x	11.0 x	9.7 x	8.5 x
Net Debt		-8	-19	-20	-42	-37	-38	-55
ROE		11.9 %	16.5 %	8.9 %	14.9 %	11.2 %	11.7 %	12.4 %
ROCE (NOPAT)		15.2 %	17.3 %	9.4 %	16.6 %	12.6 %	13.0 %	13.9 %
Guidance:	Net income m	oderately lov	ver than prio	year on a co	omparable b	asis		







Company Background

- Deutsche Beteiligungs AG (DBAG) is a publicly-listed private equity firm sponsoring management buyouts (MBOs) and financing expansion capital.
- DBAG's business model of investing its own funds alongside those of co-investment funds helps to achieve broader diversification while earning management fees which cover most of DBAG's basic operating costs.

Competitive Quality

- DBAG has a tight focus on mainly direct investments in unlisted, operationally healthy German Mittelstand companies in the industrials and services sector with sales volumes of EUR 50m 500m p.a.
- Differentiation is based on DBAG's long-standing track record. Since it was founded in 1965, DBAG has made more than 300 private equity investments.
- Investors value this experience which cannot be matched by new entrants and the very solid track record of generating a 15-year average return for shareholders above 15%.





Source: Deutsche Beteiligungs AG, Warburg Research

Deutsche Beteiligungs AG



Valuation							
	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/19e
Price / Book	0.9 x	0.9 x	1.2 x	1.0 x	1.2 x	1.1 x	1.0 x
Book value per share ex intangibles	20.31	22.15	22.12	26.85	26.26	28.27	30.73
EV / Sales	4.3 x	3.7 x	7.4 x	4.3 x	6.0 x	5.5 x	n.a.
EV / EBITDA	7.5 x	5.6 x	13.4 x	6.7 x	9.9 x	8.8 x	n.a.
EV / EBIT	7.6 x	5.6 x	13.4 x	6.7 x	9.9 x	8.8 x	n.a.
EV / EBIT adj.*	7.6 x	5.6 x	13.4 x	6.7 x	9.9 x	8.8 x	n.a.
P/FCF	n.a.	n.a.	56.2 x	659.3 x	38.9 x	25.6 x	23.3 x
P/E	8.2 x	6.0 x	14.0 x	7.6 x	11.0 x	9.7 x	8.5 x
P / E adj.*	9.2 x	6.9 x	14.0 x	7.6 x	11.0 x	9.7 x	8.5 x
Dividend Yield	6.2 %	9.5 %	3.6 %	4.3 %	3.9 %	3.9 %	3.9 %
Free Cash Flow Yield Potential	13.1 %	17.8 %	7.5 %	15.0 %	10.1 %	11.3 %	n.a.
*Adjustments made for: -							

Company Specific Items									
	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/19e		
NAV per share	20.32	22.16	22.16	26.91	26.32	28.33	30.79		
Return on NAV	11.2 %	15.9 %	9.9 %	27.2 %	2.4 %	12.8 %	13.5 %		
Net result investment activity	41	55	29	60	43	46	54		
Fee income fund services	19	22	19	18	29	33	32		
Net result of fund services and investment activity	60	76	48	78	72	78	87		




Consolidated profit & loss							
In EUR m	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/196
Net result of fund services and investment activity	60	76	48	78	72	78	87
Net result investment activity	41	55	29	60	43	46	54
Fee income fund services	19	22	19	18	29	33	32
Personnel expenses	14	17	15	16	17	17	18
Other operating income	6	10	7	7	6	7	-
Other operating expenses	18	18	13	19	18	18	20
Unfrequent items	0	0	0	0	0	0	(
EBITDA	34	48	27	51	44	49	56
Margin	56.9 %	66.1 %	55.3 %	64.4 %	60.9 %	62.9 %	64.7 %
Depreciation of fixed assets	0	0	0	0	0	0	(
EBITA	34	48	27	51	44	49	50
Amortisation of intangible assets	0	0	0	0	0	0	(
Goodwill amortisation	0	0	0	0	0	0	(
EBIT	34	48	27	51	44	49	56
Margin	56.2 %	66.1 %	55.3 %	64.4 %	60.9 %	62.9 %	64.7 %
EBIT adj.	34	48	27	51	44	49	56
Interest income	1	0	0	0	0	0	(
Interest expenses	1	0	0	1	1	1	•
Other financial income (loss)	0	0	0	0	0	0	(
EBT	34	48	27	50	43	49	55
Margin	56.4 %	66.4 %	55.9 %	63.7 %	60.2 %	62.3 %	64.1 %
Total taxes	0	0	0	0	0	0	(
Net income from continuing operations	33	48	27	50	43	48	55
Income from discontinued operations (net of tax)	0	0	0	0	0	0	(
Net income before minorities	33	48	27	50	43	48	55
Minority interest	1	0	0	0	0	0	(
Net income	32	48	27	50	43	48	55
Margin	53.9 %	65.8 %	55.8 %	63.9 %	59.7 %	61.7 %	63.6 %
Number of shares, average	14	14	14	14	15	15	15
EPS	2.36	3.51	1.98	3.65	2.84	3.21	3.66
EPS adj.	2.09	3.04	1.98	3.65	2.84	3.21	3.66
*Adjustments made for:							

Guidance: Net income moderately lower than prior year on a comparable basis

Financial Ratios							
	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/19e
EBITDA / Interest expenses	41.0 x	307.1 x	171.7 x	86.4 x	74.7 x	84.0 x	93.3 x
Tax rate (EBT)	1.4 %	0.8 %	0.1 %	-0.3 %	0.9 %	0.8 %	0.7 %
Dividend Payout Ratio	49.3 %	57.0 %	50.6 %	32.8 %	42.2 %	37.4 %	32.8 %


Net result fund services & investments





Source: Warburg Research

Performance per Share




Source: Warburg Research



Consolidated balance sheet							
In EUR m	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/196
Assets							
Goodwill and other intangible assets	0	0	1	1	1	1	1
thereof other intangible assets	0	0	0	0	0	0	(
thereof Goodwill	0	0	0	0	0	0	(
Property, plant and equipment	1	1	1	1	2	2	3
Financial assets	243	245	277	330	360	389	409
Other long-term assets	0	0	0	0	0	0	C
Fixed assets	244	246	279	332	363	393	413
Inventories	0	0	0	0	0	0	C
Accounts receivable	0	0	0	0	0	0	C
Liquid assets	11	28	28	57	53	53	70
Other short-term assets	43	58	20	15	15	15	15
Current assets	54	86	49	73	68	69	86
Total Assets	299	333	327	405	431	461	498
Liabilities and shareholders' equity							
Subscribed capital	49	49	49	53	53	53	53
Capital reserve	141	141	141	174	174	174	174
Retained earnings	2	-5	-4	32	59	89	126
Other equity components	86	118	117	110	110	110	110
Shareholders' equity	278	303	303	370	396	426	463
Minority interest	0	0	0	0	0	0	0
Total equity	278	303	303	370	396	426	463
Provisions	17	29	23	32	32	32	32
thereof provisions for pensions and similar obligations	3	9	9	16	16	16	16
Financial liabilities (total)	0	0	0	0	0	0	0
thereof short-term financial liabilities	0	0	0	0	0	0	0
Accounts payable	0	0	0	0	0	0	0
Other liabilities	4	1	1	2	2	2	2
Liabilities	21	30	24	35	35	35	35
Total liabilities and shareholders' equity	299	333	327	405	431	461	498

Financial Ratios							
	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/19e
Efficiency of Capital Employment							
ROA	13.2 %	19.5 %	9.7 %	15.1 %	11.8 %	12.3 %	13.3 %
Return on Capital							
NAV per share	20.32	22.16	22.16	26.91	26.32	28.33	30.79
Return on NAV	11.2 %	15.9 %	9.9 %	27.2 %	2.4 %	12.8 %	13.5 %
ROCE (NOPAT)	15.2 %	17.3 %	9.4 %	16.6 %	12.6 %	13.0 %	13.9 %
ROE	11.9 %	16.5 %	8.9 %	14.9 %	11.2 %	11.7 %	12.4 %
Adj. ROE	10.5 %	14.3 %	8.9 %	14.9 %	11.2 %	11.7 %	12.4 %
Balance sheet quality							
Net Debt	-8	-19	-20	-42	-37	-38	-55
Net Financial Debt	-11	-28	-28	-57	-53	-53	-70
Net Gearing	-2.9 %	-6.3 %	-6.4 %	-11.3 %	-9.4 %	-8.8 %	-11.8 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	20.3	22.2	22.2	26.9	26.3	28.3	30.8
Book value per share ex intangibles	20.3	22.1	22.1	26.8	26.3	28.3	30.7





Consolidated cash flow statement							
In EUR m	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/19
Net income	32	48	27	50	43	48	55
Depreciation of fixed assets	0	0	0	0	0	0	(
Amortisation of goodwill	0	0	0	0	0	0	(
Amortisation of intangible assets	0	0	0	0	0	0	(
Increase/decrease in long-term provisions	0	0	-1	10	0	0	(
Other non-cash income and expenses	-45	-48	-19	-59	-30	-29	-35
Cash Flow before NWC change	-12	0	7	1	13	19	21
Increase / decrease in inventory	0	0	0	0	0	0	(
Increase / decrease in accounts receivable	0	0	0	0	0	0	(
Increase / decrease in accounts payable	0	0	0	0	0	0	(
Increase / decrease in other working capital positions	0	0	0	0	0	0	(
Increase / decrease in working capital (total)	0	0	0	0	0	0	(
Net cash provided by operating activities [1]	-12	0	7	1	13	19	21
Investments in intangible assets	0	0	0	0	0	0	C
Investments in property, plant and equipment	-1	-1	-1	-1	-1	-1	-1
Payments for acquisitions	0	0	0	0	0	0	(
Financial investments	47	116	93	51	50	50	50
Income from asset disposals	67	150	114	56	50	50	65
Net cash provided by investing activities [2]	20	33	20	4	-1	-1	15
Change in financial liabilities	0	0	0	0	0	0	(
Dividends paid	-16	-16	-27	-14	-16	-18	-18
Purchase of own shares	0	0	0	0	0	0	(
Capital measures	0	0	0	37	0	0	(
Other	0	0	0	0	0	0	(
Net cash provided by financing activities [3]	-16	-16	-27	24	-16	-18	-18
Change in liquid funds [1]+[2]+[3]	-8	17	0	29	-4	0	17
Effects of exchange-rate changes on cash	0	0	0	0	0	0	C
Cash and cash equivalent at end of period	14	28	28	57	53	53	70

Financial Ratios							
	2012/13	2013/14	2014/15	2015/16	2016/17e	2017/18e	2018/19e
Cash Flow							
FCF	-12	-1	6	0	12	18	20
Interest Received / Avg. Cash	1.6 %	1.8 %	1.6 %	0.2 %	0.2 %	0.2 %	0.2 %
Interest Paid / Avg. Debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Deutsche Beteiligungs AG



LEGAL DISCLAIMER

This research report ("investment recommendation" or "recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §34B OF THE GERMAN SECURITIES TRADING ACT (WHPG), THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV) AND MAR INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.
- 3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.
- 4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 34b of the German Securities Trading Act (WpHG), the Ordinance on the Analysis of Financial Instruments (FinAnV), MAR and Commission Delegated Regulation (EU) regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5**% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6- Companies affiliated with Warburg Research regularly trade financial instruments of the analysed company or derivatives of these.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Deutsche Beteiligungs AG	3, 5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A1TNUT7.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_ "	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	122	64
Hold	65	34
Sell	4	2
Rating suspended	1	1
Total	192	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	28	74
Hold	9	24
Sell	0	0
Rating suspended	1	3
Total	38	100

PRICE AND RATING HISTORY DEUTSCHE BETEILIGUNGS AG AS OF 22.12.2016



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



FOURTIES			
EQUITIES Roland Rapelius	+49 40 3282-2673		
Head of Equities	rrapelius@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Henrik Paganetty Telecommunications	+49 40 309537-185 hpaganetty@warburg-research.com
Henner Rüschmeier	+49 40 309537-270	Andreas Pläsier	+49 40 309537-246
Head of Research	hrueschmeier@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Lucas Boventer Renewables, Internet, Media	+49 40 309537-290 lboventer@warburg-research.com	Jochen Reichert Telco, Internet, Media	+49 40 309537-130 jreichert@warburg-research.com
Christian Cohrs	+49 40 309537-175	J. Moritz Rieser	+49 40 309537-260
Engineering, Logistics Felix Ellmann	ccohrs@warburg-research.com +49 40 309537-120	Real Estate Arash Roshan Zamir	mrieser@warburg-research.com +49 40 309537-155
Software, IT	fellmann@warburg-research.com	Cap. Goods, Renewables	aroshanzamir@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Marie-Thérèse Grübner	+49 40 309537-240	Oliver Schwarz	+49 40 309537-250
Small Cap Research	mgruebner@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
Harald Hof Medtech	+49 40 309537-125 hhof@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Ulrich Huwald	+49 40 309537-255	Björn Voss	+49 40 309537-254
Health Care, Pharma	uhuwald@warburg-research.com	Steel, Car Suppliers	bvoss@warburg-research.com
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com	Alexander Wahl Car Suppliers, Technology	+49 40 309537-230 awahl@warburg-research.com
Eggert Kuls Engineering	+49 40 309537-256 ekuls@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
INSTITUTIONAL EQU		<u>, </u>	<u> </u>
Holger Nass	+49 40 3282-2669	Michael Kriszun	+49 40 3282-2695
Head of Equity Sales, USA	hnass@mmwarburg.com	United Kingdom	mkriszun@mmwarburg.com
Klaus Schilling	+49 40 3282-2664	Marc Niemann	+49 40 3282-2660
Dep. Head of Equity Sales, GER Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665	Germany Sanjay Oberoi	mniemann@mmwarburg.com +49 69 5050-7410
United Kingdom	tbeckmann@mmwarburg.com	United Kingdom	soberoi@mmwarburg.com
Lyubka Bogdanova	+49 69 5050-7411	Simon Pallhuber	+49 69 5050-7414
United Kingdom, Australia	lbogdanova@mmwarburg.com	Switzerland, France	spallhuber@mmwarburg.com
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com	Fabian Roggemann USA	+49 40 3282-2667 froggemann@mmwarburg.com
Paul Dontenwill	+49 40 3282-2666	Angelika Flegler	+49 69 5050-7417
USA	pdontenwill@mmwarburg.com	Roadshow/Marketing	aflegler@mmwarburg.com
Matthias Fritsch	+49 40 3282-2696	Juliane Willenbruch	+49 40 3282-2694
United Kingdom	mfritsch@mmwarburg.com	Roadshow/Marketing	jwillenbruch@mmwarburg.com
SALES TRADING			
Oliver Merckel	+49 40 3282-2634	Bastian Quast	+49 40 3282-2701
Head of Sales Trading	omerckel@mmwarburg.com	Sales Trading	bquast@mmwarburg.com
Elyaz Dust Sales Trading	+49 40 3282-2702 edust@mmwarburg.com	Jörg Treptow Sales Trading	+49 40 3262-2658 jtreptow@mmwarburg.com
Michael Ilgenstein	+49 40 3282-2700	Jan Walter	+49 40 3262-2662
Sales Trading	milgenstein@mmwarburg.com	Sales Trading	jwalter@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be	found under:		
Warburg Research	research.mmwarburg.com/en/index.html	Thomson Reuters	www.thomsonreuters.com
Bloomberg	MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please cont	tact:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com